Clinical Trial Detail

NCT ID NCT02443077
Title Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors National Cancer Institute (NCI)
Indications

B-cell lymphoma

diffuse large B-cell lymphoma

Therapies

Cyclophosphamide

Carmustine + Cytarabine + Etoposide + Melphalan

Ibrutinib

Age Groups: adult

No variant requirements are available.